Clinical trials: Cancer of the Prostate
- Condition Cancer of the Prostate
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Prostate Cancer
Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing
Medicare is requesting outcome data on patients who received Prolaris testing and were prescribed active surveillance (AS). In order to ensure appropriate patient care, it is important to understand how this added prognostic…
- Trial name
- URO-009Low (NCT03511235)
- Where
- 8 sites in United States
- Volunteers
- 774 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Prostate Cancer, Hormone Refractory Prostate Cancer
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00510718
- Testing
- MDV3100
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Gynaecomastia, Prostate Cancer
Casodex - Nolvadex Combination
This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex.
- Trial name
- NCT00637871
- Testing
- Casodex, Tamoxifen
- Sponsor
- AstraZeneca
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Metastatic Castration-Resistant Prostate Cancer
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this treatment protocol is to provide expanded access to MDV3100 and monitor its safety in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT01606982
- Testing
- MDV3100
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostatic Neoplasm
Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Efficacy and safety of a triptorelin 6-month formulation in patients with advanced prostate cancer. It was assumed that during the study treatment >90% of the patients would achieve and maintain castrate levels of serum…
- Trial name
- NCT00751790
- Testing
- triptorelin embonate (INN)
- Where
- South Africa
- Volunteers
- 120 people
- Sponsor
- Debiopharm International SA
Prostate Cancer
Clinical Utility Study for MyProstateScore+
This is a national-level research study of urologists. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.
- Trial name
- NCT05525806
- Testing
- Education Materials for MyProstateScore
- Where
- United States
- Volunteers
- 234 people
- Sponsor
- Qure Healthcare, LLC
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Prostate Cancer
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
The influence of Decipher test on urologist and patient treatment plan choices immediately post RP and at the time of PSA rise or BCR
- Trial name
- PRO-IMPACT (NCT02080689)
- Testing
- Decipher
- Where
- 19 sites in United States
- Volunteers
- 286 people
- Sponsor
- GenomeDx Biosciences Corp
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Prostate Cancer, Osteoporosis
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen
- Trial name
- NCT01025479
- Where
- 18 sites in South Korea
- Volunteers
- 829 people
- Sponsor
- AstraZeneca
Carcinoma
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy.
- Trial name
- NCT01614002
- Where
- 23 sites in Germany
- Volunteers
- 371 people
- Sponsor
- Onkovis GmbH
Prostate Cancer
Safety and Efficacy of Firmagon® (Degarelix) for Injection
The purpose of this study is to assess the safety and efficacy of Firmagon® (degarelix) for injection under the conditions of general clinical practice in Korea.
- Trial name
- NCT02886598
- Testing
- degarelix
- Where
- South Korea
- Volunteers
- 368 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Imaging of Residual Tumor During Prostatectomy
Prostate Cancer is the most common cancer in men, affecting about as many men as women diagnosed with breast cancer, and killing about as many men per year as breast cancer kills women.
- Trial name
- NCT01173146
- Where
- United States
- Sponsor
- Spectros Corporation
Benign Prostatic Hyperplasia, Localized Prostate Cancer
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are…
- Trial name
- NCT06051942
- Testing
- Robotic Waterjet Treatment
- Where
- 6 sites in United States, Hong Kong and 2 more
- Volunteers
- 125 people
- Sponsor
- PROCEPT BioRobotics
Prostate Cancer Patients Treated by Radiotherapy
Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial
This study is testing a shorter treatment method for prostate cancer using proton therapy (PT), which is very precise and may cause fewer side effects compared to traditional radiation.
- Trial name
- PT2 (NCT07130682)
- Testing
- Pencil Beam Proton Therapy Treatment Machine
- Where
- Hong Kong
- Volunteers
- 35 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Prostate Cancer
CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy
This multicenter retrospective observational study aims to compare perioperative and postoperative outcomes between the da Vinci SP extraperitoneal approach (SP-EA) and the robotic multi-port transperitoneal approach (MP-TA) in…
- Trial name
- CoSMAP (NCT07666217)
- Where
- 8 sites in Japan
- Volunteers
- 625 people
- Sponsor
- Intuitive Surgical
Bone Cancer, Bone Tumor
A Dose Finding Study to Treat Bone Tumor(s)
To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects…
- Conditions
- Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone
- Trial name
- NCT06008483
- Testing
- 153-Sm-DOTMP (Samarium-153-DOTMP)
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- QSAM Therapeutics, Inc.
Prostate Cancer
Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
Tremodi is an observational, non-interventional, prospective, open-label, non-comparative study that will collect real life data of a treatment with Depo-Eligard® in 3 different administrations in male prostate cancer patients.
- Trial name
- TREMODI (NCT01793077)
- Testing
- Depo-Eligard®
- Where
- 23 sites in Belgium
- Volunteers
- 259 people
- Sponsor
- Astellas Pharma Europe B.V.
Locally Advanced Prostate Cancer
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
While radiation therapy with androgen ablation (hormone reduction) is the standard method of treating locally advanced prostate cancer.
- Trial name
- NCT01048151
- Testing
- TNFerade™ Biologic
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GenVec